Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with obesity or overweight and ...

Per its agreement with Gubra A/S, AbbVie will lead the development of GUB014295. Gubra A/S received an upfront payment of $350 million and could get up to $1.9 billion in various development ...